Objectives: To assess whether low-dose ritonavir-boosted darunavir (darunavir/r) in combination with two NRTIs could maintain virological suppression in patients on a standard regimen of darunavir/r + two NRTIs.
Design: A multicentre, Phase II, non-comparative, single-arm, open-label study.
Setting: Tertiary care hospitals in France.